These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10487504)

  • 1. Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance.
    Elkeles RS; Diamond JR; Anyaoku V; Hughes C; Richmond W
    Atherosclerosis; 1999 Sep; 146(1):195-6. PubMed ID: 10487504
    [No Abstract]   [Full Text] [Related]  

  • 2. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
    Jeck T; Riesen WF; Keller U
    Diabet Med; 1997 Jul; 14(7):564-70. PubMed ID: 9223394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 6. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
    Gavish D; Leibovitz E; Shapira I; Rubinstein A
    J Intern Med; 2000 May; 247(5):563-9. PubMed ID: 10809995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of simvastatin and bezafibrate on bile composition and gall-bladder emptying in female non-insulin-dependent diabetics.
    Wilson IR; Hurrell MA; Pattinson NR; Chapman BA
    J Gastroenterol Hepatol; 1994; 9(5):447-51. PubMed ID: 7827294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
    Ogawa S; Takeuchi K; Sugimura K; Fukuda M; Lee R; Ito S; Sato T
    Metabolism; 2000 Mar; 49(3):331-4. PubMed ID: 10726910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 11. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus.
    Taskinen MR; Lahdenperä S; Syvänne M
    Ann Med; 1996 Aug; 28(4):335-40. PubMed ID: 8862688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 13. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
    Papadakis JA; Milionis HJ; Press M; Mikhailidis DP
    J Diabetes Complications; 2001; 15(4):211-26. PubMed ID: 11457674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
    Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
    Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
    Watts GF; Dimmitt SB; Barter PJ
    Med J Aust; 2001 Jan; 174(2):66-7. PubMed ID: 11245504
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
    Nakandakare E; Garcia RC; Rocha JC; Sperotto G; Oliveira HC; Quintão EC
    Atherosclerosis; 1990 Dec; 85(2-3):211-7. PubMed ID: 2102085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 inhibitors- A new age in lipid management?
    Grant PJ
    Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
    Rovellini A; Sommariva D; Branchi A; Maraffi F; Montalto C; Gandini R; Fasoli A
    Pharmacol Res; 1992 Apr; 25(3):237-45. PubMed ID: 1518767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.